Evidence map›Paper›PMID 30813205›Full record

ArticleMedicine2019

Yinchenhao decoction for chronic hepatitis B: Protocol for a systematic review and meta-analysis.

Lu Xu, Tian Xie, Tao Shen, Shengnan Jian

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. [Analysis of core functional components inNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  3. Article
  4. A Network Pharmacology Approach to Explore the Mechanisms ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lu XuSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
Tian XieShenzhen Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Tao ShenSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
Shengnan JianSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
Chengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic hepatitis B (CHB) is a very critical threat to public health worldwide, and is the primary cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Yinchenhao decoction (YCHD) is a classic prescription of traditional Chinese medicine for the treatment of jaundice. Despite the satisfactory clinical efficacy of YCHD in the treatment of CHB, the safety of YCHD is still uncertain. Therefore, we will provide a systematic review of YCHD in CHB treatments.

methodsThe purpose of this review is to retrieve relevant literature on YCHD therapy for CHB in the electrical databases, including 4 Chinese databases (e.g., Wanfang database, Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical database (CBM), Chinese Science and Technology Periodical database (VIP)) and 3 English databases (e.g., PubMed, Cochrane Library, and EMBASE). The literatures involved are from the establishment of the databases to January 2019. The primary outcomes are HBV-DNA, HBeAg, and ALT. We will calculate the data synthesis for meta-analysis using RevMan V.5.3 software if the results are suitable.

resultsThis study will offer a high-quality composite of existing evidence for YCHD in CHB treatment according to HBV-DNA quantitative detection, HBeAg qualitative detection, ALT levels, TCM syndrome evaluation criteria, status changes in quality of life assessment participants, and adverse events.

conclusionThis systematic review will provide evidence to assess the clinical efficacy of YCHD in the treatment of patients with CHB. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42019119720.

Indexed as

Drugs, Chinese HerbalHepatitis B, ChronicMedicine, Chinese TraditionalChinaDatabases, FactualGastrointestinal AgentsHumansMeta-Analysis as TopicSystematic Reviews as TopicTreatment OutcomeDrugs, Chinese HerbalGastrointestinal Agentsyinchenhao

Identifiers

PMID30813205
PMCPMC6408079
OpenAlexW2918530565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.